
DWTX Stock Forecast & Price Target
DWTX Analyst Ratings
Bulls say
Dogwood Therapeutics is a development-stage biopharmaceutical company with a positive outlook due to its strong pipeline of potential treatments for chronic neuropathic pain and neuropathy, a significant unmet medical need. The company's licensing of its anti-viral assets to PridCor Therapeutics provides potential for future milestone payments and royalties. However, the lack of near-term clinical milestones may limit immediate impact and the stock's potential growth.
Bears say
Dogwood Therapeutics is a development-stage biopharmaceutical company with a focus on treating chronic neuropathic pain and neuropathy. Despite its promising pipeline, the company has yet to generate any revenues and is still in the pre-revenue stage. With a projected net loss of $0.56 per share for 2026 and only $13.2 million in cash and cash equivalents, the stock may face challenges in the near future.
This aggregate rating is based on analysts' research of Dogwood Therapeutics, Inc. and is not a guaranteed prediction by Public.com or investment advice.
DWTX Analyst Forecast & Price Prediction
Start investing in DWTX
Order type
Buy in
Order amount
Est. shares
0 shares